Chemfab Alkalis Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹75.61 Cr (-1.24% YoY, +3.35% QoQ); operational EBITDA ₹7.04 Cr at 9.31% margin; PBT loss ₹2.95 Cr. Chemicals recovery offset by OPVC collapse.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements with these filters
Q2FY27 consolidated revenue ₹75.61 Cr (-1.24% YoY, +3.35% QoQ); operational EBITDA ₹7.04 Cr at 9.31% margin; PBT loss ₹2.95 Cr. Chemicals recovery offset by OPVC collapse.
Chemfab Alkalis approved unaudited Q2/H1 results, committee re-designations, and appointed V. R. Raguraman as Chief Operating Officer (SMP). The senior management appointment is the filing's main business event.
Chemfab Alkalis Ltd reported revenue from operations of ₹75.6 Cr (-1.3% YoY) and a net loss of ₹2.1 Cr for Q2 FY27.
Chemfab Alkalis Ltd has scheduled a board meeting on October 28, 2026, to approve the standalone and consolidated financial results for the quarter ended September 30, 2026.
Chemfab Alkalis Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing discloses the company's equity distribution as per Regulation 31.
India Ratings affirmed Chemfab Alkalis' bank loan facilities at IND BBB+/Negative. The action reflects expected operational recovery against a still-stretched liquidity position.
Chemfab Alkalis Limited's shareholders approved the appointment of M/s. MSKC & Associates LLP as Statutory Auditors for a five-year term at the 17th AGM.
Chemfab Alkalis held its 17th Annual General Meeting on September 9, 2026. Shareholders transacted ordinary and special business as set out in the notice.
Chemfab Alkalis Limited has dispatched letters to shareholders providing a web-link for accessing the FY 2025-26 Annual Report. This applies to shareholders without registered email addresses.
Chemfab Alkalis Limited has fixed September 2, 2026, as the record date for final dividend eligibility. The dividend is subject to shareholder approval at the upcoming AGM.
Chemfab Alkalis Limited has submitted its Annual Report for the financial year 2025-26. The 17th Annual General Meeting is scheduled for 09th September 2026.
Chemfab Alkalis Limited has scheduled its 17th Annual General Meeting for September 9, 2026, to conduct ordinary and special business, including a dividend declaration.